Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Liver glucose production encompasses the biochemical processes by which the liver maintains blood sugar levels during fasting or increased energy demand. The two main mechanisms are: 1. Glycogenolysis — breakdown of stored glycogen into free glucose. 2. Gluconeogenesis — synthesis of new glucose molecules from precursors such as lactate, alanine, glycerol. Key enzymatic steps involve conversion between metabolites regulated tightly at transcriptional and post-translational levels. Important enzymes include: - Glucokinase phosphorylates incoming free glucose for intracellular metabolism. - Pyruvate carboxylase converts pyruvate into oxaloacetate initiating gluconeogenic flux. - Phosphoenolpyruvate carboxykinase catalyzes formation of phosphoenolpyruvate from oxaloacetate. - Fructose bisphosphatases regulate rate-limiting steps reversing glycolytic reactions. – Glucose‑6‑phosphatase finalizes dephosphorylation releasing free circulating glucose. Hormonal control plays a critical role with insulin suppressing while glucagon stimulates these pathways. Dysregulation leads to pathological states such as diabetes where excessive hepatic output contributes significantly to hyperglycemia[1][3][5][7]. In summary, "Liver Glucose Production" should be understood as an essential metabolic function rather than an individual molecular target suitable for direct drug binding but remains central in therapeutic strategies aimed at controlling systemic glycemic balance[1][3][5].
Drugs targeting this process mainly act by: - Inhibiting key gluconeogenic enzymes or their gene expression - Enhancing insulin signaling to suppress gluconeogenesis/glycogenolysis For example: * Metformin decreases hepatic gluconeogenesis without increasing insulin secretion; exact mechanism remains partially unclear but involves AMP kinase activation and mitochondrial effects. * Insulin inhibits glycogen breakdown and promotes glycogen synthesis in hepatocytes.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Liver glucose production (None).